HEADER KINASE 26-JUN-03 1OIU TITLE STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6- TITLE 2 CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR COMPND MOL_ID: 1; COMPND 2 MOLECULE: CELL DIVISION PROTEIN KINASE 2; COMPND 3 CHAIN: A, C; COMPND 4 SYNONYM: P33 PROTEIN KINASE, CDK2; COMPND 5 EC: 2.7.1.37; COMPND 6 ENGINEERED: YES; COMPND 7 OTHER_DETAILS: PHOSPHORYLATED ON THR160; COMPND 8 MOL_ID: 2; COMPND 9 MOLECULE: CYCLIN A2; COMPND 10 CHAIN: B, D; COMPND 11 FRAGMENT: RESIDUES 174-432; COMPND 12 SYNONYM: CYCLIN A, CCNA2, CCNA, CCN1; COMPND 13 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 7 MOL_ID: 2; SOURCE 8 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 9 ORGANISM_COMMON: HUMAN; SOURCE 10 ORGANISM_TAXID: 9606; SOURCE 11 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 12 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS KINASE, TRANSFERASE, SERINE/THREONINE-PROTEIN KINASE, ATP-BINDING, KEYWDS 2 CELL CYCLE, CELL DIVISION, MITOSIS, PHOSPHORYLATION EXPDTA X-RAY DIFFRACTION AUTHOR D.J.PRATT,J.A.ENDICOTT,M.E.M.NOBLE REVDAT 4 06-NOV-24 1OIU 1 REMARK REVDAT 3 13-DEC-23 1OIU 1 LINK REVDAT 2 24-FEB-09 1OIU 1 VERSN REVDAT 1 13-JUL-04 1OIU 0 JRNL AUTH I.R.HARDCASTLE,C.E.ARRIS,J.BENTLEY,F.T.BOYLE,Y.CHEN, JRNL AUTH 2 N.J.CURTIN,J.A.ENDICOTT,A.E.GIBSON,B.T.GOLDING,R.J.GRIFFIN, JRNL AUTH 3 P.JEWSBURY,J.MENYEROL,V.MESGUICHE,D.R.NEWELL,M.E.M.NOBLE, JRNL AUTH 4 D.J.PRATT,L.-Z.WANG,H.J.WHITFIELD JRNL TITL N2-SUBSTITUTED O6-CYCLOHEXYLMETHYLGUANINE DERIVATIVES: JRNL TITL 2 POTENT INHIBITORS OF CYCLIN-DEPENDENT KINASES 1 AND 2 JRNL REF J.MED.CHEM. V. 47 3710 2004 JRNL REFN ISSN 0022-2623 JRNL PMID 15239650 JRNL DOI 10.1021/JM0311442 REMARK 2 REMARK 2 RESOLUTION. 2.00 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.00 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 100.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 99.1 REMARK 3 NUMBER OF REFLECTIONS : 93478 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : NULL REMARK 3 R VALUE (WORKING SET) : 0.216 REMARK 3 FREE R VALUE : 0.253 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.030 REMARK 3 FREE R VALUE TEST SET COUNT : 4923 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 8649 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 69 REMARK 3 SOLVENT ATOMS : 646 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 26.73 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 27.84 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.51000 REMARK 3 B22 (A**2) : 0.34000 REMARK 3 B33 (A**2) : 0.17000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.181 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.164 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.105 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 3.638 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 DISTANCE RESTRAINTS. RMS SIGMA REMARK 3 BOND LENGTH (A) : NULL ; NULL REMARK 3 ANGLE DISTANCE (A) : NULL ; NULL REMARK 3 INTRAPLANAR 1-4 DISTANCE (A) : NULL ; NULL REMARK 3 H-BOND OR METAL COORDINATION (A) : NULL ; NULL REMARK 3 REMARK 3 PLANE RESTRAINT (A) : NULL ; NULL REMARK 3 CHIRAL-CENTER RESTRAINT (A**3) : NULL ; NULL REMARK 3 REMARK 3 NON-BONDED CONTACT RESTRAINTS. REMARK 3 SINGLE TORSION (A) : NULL ; NULL REMARK 3 MULTIPLE TORSION (A) : NULL ; NULL REMARK 3 H-BOND (X...Y) (A) : NULL ; NULL REMARK 3 H-BOND (X-H...Y) (A) : NULL ; NULL REMARK 3 REMARK 3 CONFORMATIONAL TORSION ANGLE RESTRAINTS. REMARK 3 SPECIFIED (DEGREES) : NULL ; NULL REMARK 3 PLANAR (DEGREES) : NULL ; NULL REMARK 3 STAGGERED (DEGREES) : NULL ; NULL REMARK 3 TRANSVERSE (DEGREES) : NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1OIU COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 26-JUN-03. REMARK 100 THE DEPOSITION ID IS D_1290012954. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 10-MAY-03 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 7.00 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID14-1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.93400 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 98449 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.000 REMARK 200 RESOLUTION RANGE LOW (A) : 74.540 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 1.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.1 REMARK 200 DATA REDUNDANCY : 3.220 REMARK 200 R MERGE (I) : 0.06100 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 7.0519 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.00 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.11 REMARK 200 COMPLETENESS FOR SHELL (%) : 97.8 REMARK 200 DATA REDUNDANCY IN SHELL : 2.35 REMARK 200 R MERGE FOR SHELL (I) : 0.24000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 3.110 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: PDB ENTRY 1H1S REMARK 200 REMARK 200 REMARK: USED DATA TO 3.5 A FOR MR REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 55.20 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.80 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.7-0.85 M POTASSIUM CHLORIDE 1.1-1.25 REMARK 280 M AMMONIUM SULFATE, 40 MM HEPES, PH 7.0 5 MM DITHIOTHREITOL, 10 REMARK 280 MG/ML PROTEIN, 8M SODIUM FORMATE CRYO-PROTECTANT, PH 7.00 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 36.82400 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 74.11400 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 66.88900 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 74.11400 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 36.82400 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 66.88900 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: C, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 CYCLIN CONTROLS THE CELL CYCLE AT THE G1/S REMARK 400 (START) AND THE G2/M (MITOSIS) TRANSITIONS. REMARK 400 KINASE INTERACTS WITH CYCLINS A, D, OR E. REMARK 400 ACTIVITY OF CDK2 IS MAXIMAL DURING S PHASE AND G2. REMARK 400 REMARK 400 THE GLUTAMIC ACID RESIDUES INDICATED IN REMARK 470 REMARK 400 BELOW HAVE MISSING ATOMS DUE TO RADIATION-INDUCED REMARK 400 DECARBOXYLATION. REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A -3 REMARK 465 ASP A 38 REMARK 465 THR A 39 REMARK 465 GLU A 40 REMARK 465 LEU A 298 REMARK 465 MET B 173 REMARK 465 GLU B 174 REMARK 465 VAL B 175 REMARK 465 PRO B 176 REMARK 465 GLY C -3 REMARK 465 PRO C -2 REMARK 465 GLY C -1 REMARK 465 THR C 221 REMARK 465 PRO C 222 REMARK 465 ASP C 223 REMARK 465 GLU C 224 REMARK 465 VAL C 225 REMARK 465 VAL C 226 REMARK 465 TRP C 227 REMARK 465 PRO C 228 REMARK 465 GLY C 229 REMARK 465 VAL C 230 REMARK 465 THR C 231 REMARK 465 SER C 232 REMARK 465 MET C 233 REMARK 465 PRO C 234 REMARK 465 ASP C 235 REMARK 465 TYR C 236 REMARK 465 LYS C 237 REMARK 465 PRO C 238 REMARK 465 SER C 239 REMARK 465 PHE C 240 REMARK 465 PRO C 241 REMARK 465 LYS C 242 REMARK 465 TRP C 243 REMARK 465 ALA C 244 REMARK 465 ARG C 245 REMARK 465 GLN C 246 REMARK 465 ASP C 247 REMARK 465 PHE C 248 REMARK 465 SER C 249 REMARK 465 LYS C 250 REMARK 465 VAL C 251 REMARK 465 ARG C 297 REMARK 465 LEU C 298 REMARK 465 MET D 173 REMARK 465 GLU D 174 REMARK 465 VAL D 175 REMARK 465 PRO D 176 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLU A 162 CD OE1 OE2 REMARK 470 GLU B 223 CD OE1 OE2 REMARK 470 GLU B 385 CD OE1 OE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O HOH A 2152 O HOH A 2180 1.39 REMARK 500 O HOH C 2021 O HOH C 2023 1.41 REMARK 500 O GLN A 246 O HOH A 2180 1.76 REMARK 500 O SER A 0 O HOH A 2001 1.78 REMARK 500 OE2 GLU C 28 O HOH C 2021 1.84 REMARK 500 O PHE A 248 O HOH A 2182 2.12 REMARK 500 OG SER A 181 O HOH A 2123 2.15 REMARK 500 O HOH C 2027 O HOH C 2028 2.16 REMARK 500 SG CYS B 193 S1 SGM B 1193 2.19 REMARK 500 O HOH A 2110 O HOH B 2093 2.19 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS THAT ARE RELATED BY CRYSTALLOGRAPHIC REMARK 500 SYMMETRY ARE IN CLOSE CONTACT. AN ATOM LOCATED WITHIN 0.15 REMARK 500 ANGSTROMS OF A SYMMETRY RELATED ATOM IS ASSUMED TO BE ON A REMARK 500 SPECIAL POSITION AND IS, THEREFORE, LISTED IN REMARK 375 REMARK 500 INSTEAD OF REMARK 500. ATOMS WITH NON-BLANK ALTERNATE REMARK 500 LOCATION INDICATORS ARE NOT INCLUDED IN THE CALCULATIONS. REMARK 500 REMARK 500 DISTANCE CUTOFF: REMARK 500 2.2 ANGSTROMS FOR CONTACTS NOT INVOLVING HYDROGEN ATOMS REMARK 500 1.6 ANGSTROMS FOR CONTACTS INVOLVING HYDROGEN ATOMS REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI SSYMOP DISTANCE REMARK 500 O HOH A 2185 O HOH B 2032 4456 1.74 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ASP A 235 CB - CG - OD2 ANGL. DEV. = 5.6 DEGREES REMARK 500 ASP A 247 CB - CG - OD2 ANGL. DEV. = 5.6 DEGREES REMARK 500 ASP A 256 CB - CG - OD2 ANGL. DEV. = 6.0 DEGREES REMARK 500 ASP C 38 CB - CG - OD2 ANGL. DEV. = 5.4 DEGREES REMARK 500 ASP C 86 CB - CG - OD2 ANGL. DEV. = 5.5 DEGREES REMARK 500 ASP C 256 CB - CG - OD2 ANGL. DEV. = 5.6 DEGREES REMARK 500 ASP D 205 CB - CG - OD2 ANGL. DEV. = 5.4 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LEU A 58 74.69 -102.23 REMARK 500 ASP A 127 40.29 -150.84 REMARK 500 ASP A 145 78.03 51.55 REMARK 500 VAL A 164 130.68 73.20 REMARK 500 SER A 181 -144.73 -146.45 REMARK 500 PHE B 304 14.18 58.83 REMARK 500 TRP B 372 110.24 -26.73 REMARK 500 GLU C 40 -15.16 67.82 REMARK 500 THR C 41 -110.80 -113.71 REMARK 500 ASP C 127 38.81 -151.33 REMARK 500 ASP C 145 77.47 45.26 REMARK 500 VAL C 164 132.71 71.75 REMARK 500 SER C 181 -147.70 -152.61 REMARK 500 THR C 290 -167.18 -126.76 REMARK 500 THR D 303 47.50 39.90 REMARK 500 TRP D 372 107.27 -25.87 REMARK 500 REMARK 500 REMARK: NULL REMARK 620 REMARK 620 METAL COORDINATION REMARK 620 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 620 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 MG B1433 MG REMARK 620 N RES CSSEQI ATOM REMARK 620 1 MET B 200 O REMARK 620 2 GLN B 203 O 84.8 REMARK 620 3 ILE B 206 O 99.6 100.6 REMARK 620 4 HOH B2050 O 83.4 160.1 97.2 REMARK 620 5 HOH B2051 O 89.4 86.4 169.0 77.5 REMARK 620 6 HOH B2052 O 173.1 98.0 86.0 92.0 84.5 REMARK 620 N 1 2 3 4 5 REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MG B1433 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE N76 A1298 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE N76 C1298 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SGM B1193 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SGM D1193 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1AQ1 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 STAUROSPORINE REMARK 900 RELATED ID: 1B38 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1B39 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160 REMARK 900 RELATED ID: 1BUH RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITHCELL CYCLE- REMARK 900 REGULATORY PROTEIN CKSHS1 REMARK 900 RELATED ID: 1CKP RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 PURVALANOL B REMARK 900 RELATED ID: 1DI8 RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4- REMARK 900 [3- HYDROXYANILINO]-6,7-DIMETHOXYQUINAZOLINE REMARK 900 RELATED ID: 1DM2 RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR REMARK 900 HYMENIALDISINE REMARK 900 RELATED ID: 1E1V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058 REMARK 900 RELATED ID: 1E1X RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027 REMARK 900 RELATED ID: 1E9H RELATED DB: PDB REMARK 900 THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE REMARK 900 INHIBITOR INDIRUBIN-5- SULPHONATE BOUND REMARK 900 RELATED ID: 1F5Q RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO REMARK 900 HUMAN CYCLIN DEPENDANT KINASE 2 REMARK 900 RELATED ID: 1FIN RELATED DB: PDB REMARK 900 CYCLIN A - CYCLIN-DEPENDENT KINASE 2 COMPLEX REMARK 900 RELATED ID: 1FQ1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) INCOMPLEX REMARK 900 WITH PHOSPHO-CDK2 REMARK 900 RELATED ID: 1FVT RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH AN REMARK 900 OXINDOLE INHIBITOR REMARK 900 RELATED ID: 1G5S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2)IN REMARK 900 COMPLEX WITH THE INHIBITOR H717 REMARK 900 RELATED ID: 1GIH RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GII RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GIJ RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4INHIBITOR REMARK 900 RELATED ID: 1GY3 RELATED DB: PDB REMARK 900 PCDK2/CYCLIN A IN COMPLEX WITH MGADP, NITRATE AND PEPTIDE SUBSTRATE REMARK 900 RELATED ID: 1GZ8 RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2- REMARK 900 AMINO-6-(3'-METHYL- 2'-OXO)BUTOXYPURINE REMARK 900 RELATED ID: 1H00 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H01 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H06 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H07 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 4, 6 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H08 RELATED DB: PDB REMARK 900 CDK2 IN COMPLEX WITH A DISUBSTITUTED 2, 4 -BIS ANILINO PYRIMIDINE REMARK 900 CDK4 INHIBITOR REMARK 900 RELATED ID: 1H0U RELATED DB: PDB REMARK 900 M. SMEGMATIS ARYLAMINE N-ACETYL TRANSFERASE REMARK 900 RELATED ID: 1H0V RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[(R )-PYRROLIDINO-5'-YL]METHOXYPURINE REMARK 900 RELATED ID: 1H0W RELATED DB: PDB REMARK 900 HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE REMARK 900 INHIBITOR 2-AMINO-6-[ CYCLOHEX-3-ENYL]METHOXYPURINE REMARK 900 RELATED ID: 1H24 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 1H25 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 E2F REMARK 900 RELATED ID: 1H26 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P53 REMARK 900 RELATED ID: 1H27 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P27 REMARK 900 RELATED ID: 1H28 RELATED DB: PDB REMARK 900 CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM REMARK 900 P107 REMARK 900 RELATED ID: 1HCK RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1HCL RELATED DB: PDB REMARK 900 HUMAN CYCLIN-DEPENDENT KINASE 2 REMARK 900 RELATED ID: 1JSV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) INCOMPLEX WITH 4- REMARK 900 [(6-AMINO-4- PYRIMIDINYL)AMINO]BENZENESULFONAMIDE REMARK 900 RELATED ID: 1JVP RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN CDK2 ( UNPHOSPHORYLATED) INCOMPLEX WITH REMARK 900 PKF049-365 REMARK 900 RELATED ID: 1KE5 RELATED DB: PDB REMARK 900 CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO- 1,2-DIHYDRO-3H-INDOL-3- REMARK 900 YLIDENE)METHYL] AMINO}BENZENESULFONAMIDE REMARK 900 RELATED ID: 1KE6 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4-[2-(7- REMARK 900 OXO-6,7-DIHYDRO -8H-[1,3]THIAZOLO[5,4-E]INDOL-8- YLIDENE)HYDRAZINO] REMARK 900 PHENYL}METHANESULFONAMIDE REMARK 900 RELATED ID: 1KE7 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(2,2-DIOXIDO-1, REMARK 900 3-DIHYDRO-2- BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3- OXAZOL-5-YL)- REMARK 900 1,3-DIHYDRO-2H-INDOL-2-ONE REMARK 900 RELATED ID: 1KE8 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO-1,2- REMARK 900 DIHYDRO-3H-INDOL-3 -YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2- YL) REMARK 900 BENZENESULFONAMIDE REMARK 900 RELATED ID: 1KE9 RELATED DB: PDB REMARK 900 CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4-({ REMARK 900 [AMINO(IMINO)METHYL] AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3- REMARK 900 DIHYDRO-1H-INDOLE REMARK 900 RELATED ID: 1QMZ RELATED DB: PDB REMARK 900 PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX REMARK 900 RELATED ID: 1FVV RELATED DB: PDB REMARK 900 THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLEINHIBITOR REMARK 900 RELATED ID: 1H1P RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU2058 REMARK 900 RELATED ID: 1H1Q RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6094 REMARK 900 RELATED ID: 1H1R RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6086 REMARK 900 RELATED ID: 1H1S RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH THE REMARK 900 INHIBITOR NU6102 REMARK 900 RELATED ID: 1JST RELATED DB: PDB REMARK 900 PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A REMARK 900 RELATED ID: 1JSU RELATED DB: PDB REMARK 900 P27(KIP1)/CYCLIN A/CDK2 COMPLEX REMARK 900 RELATED ID: 1OGU RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/ CYCLIN A COMPLEXED WITH A 2- REMARK 900 ARYLAMINO-4- CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR DBREF 1OIU A -3 0 PDB 1OIU 1OIU -3 0 DBREF 1OIU A 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 1OIU B 173 173 PDB 1OIU 1OIU 173 173 DBREF 1OIU B 174 432 UNP P20248 CGA2_HUMAN 174 432 DBREF 1OIU C -3 0 PDB 1OIU 1OIU -3 0 DBREF 1OIU C 1 298 UNP P24941 CDK2_HUMAN 1 298 DBREF 1OIU D 173 173 PDB 1OIU 1OIU 173 173 DBREF 1OIU D 174 432 UNP P20248 CGA2_HUMAN 174 432 SEQRES 1 A 302 GLY PRO GLY SER MET GLU ASN PHE GLN LYS VAL GLU LYS SEQRES 2 A 302 ILE GLY GLU GLY THR TYR GLY VAL VAL TYR LYS ALA ARG SEQRES 3 A 302 ASN LYS LEU THR GLY GLU VAL VAL ALA LEU LYS LYS ILE SEQRES 4 A 302 ARG LEU ASP THR GLU THR GLU GLY VAL PRO SER THR ALA SEQRES 5 A 302 ILE ARG GLU ILE SER LEU LEU LYS GLU LEU ASN HIS PRO SEQRES 6 A 302 ASN ILE VAL LYS LEU LEU ASP VAL ILE HIS THR GLU ASN SEQRES 7 A 302 LYS LEU TYR LEU VAL PHE GLU PHE LEU HIS GLN ASP LEU SEQRES 8 A 302 LYS LYS PHE MET ASP ALA SER ALA LEU THR GLY ILE PRO SEQRES 9 A 302 LEU PRO LEU ILE LYS SER TYR LEU PHE GLN LEU LEU GLN SEQRES 10 A 302 GLY LEU ALA PHE CYS HIS SER HIS ARG VAL LEU HIS ARG SEQRES 11 A 302 ASP LEU LYS PRO GLN ASN LEU LEU ILE ASN THR GLU GLY SEQRES 12 A 302 ALA ILE LYS LEU ALA ASP PHE GLY LEU ALA ARG ALA PHE SEQRES 13 A 302 GLY VAL PRO VAL ARG THR TYR TPO HIS GLU VAL VAL THR SEQRES 14 A 302 LEU TRP TYR ARG ALA PRO GLU ILE LEU LEU GLY CYS LYS SEQRES 15 A 302 TYR TYR SER THR ALA VAL ASP ILE TRP SER LEU GLY CYS SEQRES 16 A 302 ILE PHE ALA GLU MET VAL THR ARG ARG ALA LEU PHE PRO SEQRES 17 A 302 GLY ASP SER GLU ILE ASP GLN LEU PHE ARG ILE PHE ARG SEQRES 18 A 302 THR LEU GLY THR PRO ASP GLU VAL VAL TRP PRO GLY VAL SEQRES 19 A 302 THR SER MET PRO ASP TYR LYS PRO SER PHE PRO LYS TRP SEQRES 20 A 302 ALA ARG GLN ASP PHE SER LYS VAL VAL PRO PRO LEU ASP SEQRES 21 A 302 GLU ASP GLY ARG SER LEU LEU SER GLN MET LEU HIS TYR SEQRES 22 A 302 ASP PRO ASN LYS ARG ILE SER ALA LYS ALA ALA LEU ALA SEQRES 23 A 302 HIS PRO PHE PHE GLN ASP VAL THR LYS PRO VAL PRO HIS SEQRES 24 A 302 LEU ARG LEU SEQRES 1 B 260 MET GLU VAL PRO ASP TYR HIS GLU ASP ILE HIS THR TYR SEQRES 2 B 260 LEU ARG GLU MET GLU VAL LYS CYS LYS PRO LYS VAL GLY SEQRES 3 B 260 TYR MET LYS LYS GLN PRO ASP ILE THR ASN SER MET ARG SEQRES 4 B 260 ALA ILE LEU VAL ASP TRP LEU VAL GLU VAL GLY GLU GLU SEQRES 5 B 260 TYR LYS LEU GLN ASN GLU THR LEU HIS LEU ALA VAL ASN SEQRES 6 B 260 TYR ILE ASP ARG PHE LEU SER SER MET SER VAL LEU ARG SEQRES 7 B 260 GLY LYS LEU GLN LEU VAL GLY THR ALA ALA MET LEU LEU SEQRES 8 B 260 ALA SER LYS PHE GLU GLU ILE TYR PRO PRO GLU VAL ALA SEQRES 9 B 260 GLU PHE VAL TYR ILE THR ASP ASP THR TYR THR LYS LYS SEQRES 10 B 260 GLN VAL LEU ARG MET GLU HIS LEU VAL LEU LYS VAL LEU SEQRES 11 B 260 THR PHE ASP LEU ALA ALA PRO THR VAL ASN GLN PHE LEU SEQRES 12 B 260 THR GLN TYR PHE LEU HIS GLN GLN PRO ALA ASN CYS LYS SEQRES 13 B 260 VAL GLU SER LEU ALA MET PHE LEU GLY GLU LEU SER LEU SEQRES 14 B 260 ILE ASP ALA ASP PRO TYR LEU LYS TYR LEU PRO SER VAL SEQRES 15 B 260 ILE ALA GLY ALA ALA PHE HIS LEU ALA LEU TYR THR VAL SEQRES 16 B 260 THR GLY GLN SER TRP PRO GLU SER LEU ILE ARG LYS THR SEQRES 17 B 260 GLY TYR THR LEU GLU SER LEU LYS PRO CYS LEU MET ASP SEQRES 18 B 260 LEU HIS GLN THR TYR LEU LYS ALA PRO GLN HIS ALA GLN SEQRES 19 B 260 GLN SER ILE ARG GLU LYS TYR LYS ASN SER LYS TYR HIS SEQRES 20 B 260 GLY VAL SER LEU LEU ASN PRO PRO GLU THR LEU ASN LEU SEQRES 1 C 302 GLY PRO GLY SER MET GLU ASN PHE GLN LYS VAL GLU LYS SEQRES 2 C 302 ILE GLY GLU GLY THR TYR GLY VAL VAL TYR LYS ALA ARG SEQRES 3 C 302 ASN LYS LEU THR GLY GLU VAL VAL ALA LEU LYS LYS ILE SEQRES 4 C 302 ARG LEU ASP THR GLU THR GLU GLY VAL PRO SER THR ALA SEQRES 5 C 302 ILE ARG GLU ILE SER LEU LEU LYS GLU LEU ASN HIS PRO SEQRES 6 C 302 ASN ILE VAL LYS LEU LEU ASP VAL ILE HIS THR GLU ASN SEQRES 7 C 302 LYS LEU TYR LEU VAL PHE GLU PHE LEU HIS GLN ASP LEU SEQRES 8 C 302 LYS LYS PHE MET ASP ALA SER ALA LEU THR GLY ILE PRO SEQRES 9 C 302 LEU PRO LEU ILE LYS SER TYR LEU PHE GLN LEU LEU GLN SEQRES 10 C 302 GLY LEU ALA PHE CYS HIS SER HIS ARG VAL LEU HIS ARG SEQRES 11 C 302 ASP LEU LYS PRO GLN ASN LEU LEU ILE ASN THR GLU GLY SEQRES 12 C 302 ALA ILE LYS LEU ALA ASP PHE GLY LEU ALA ARG ALA PHE SEQRES 13 C 302 GLY VAL PRO VAL ARG THR TYR TPO HIS GLU VAL VAL THR SEQRES 14 C 302 LEU TRP TYR ARG ALA PRO GLU ILE LEU LEU GLY CYS LYS SEQRES 15 C 302 TYR TYR SER THR ALA VAL ASP ILE TRP SER LEU GLY CYS SEQRES 16 C 302 ILE PHE ALA GLU MET VAL THR ARG ARG ALA LEU PHE PRO SEQRES 17 C 302 GLY ASP SER GLU ILE ASP GLN LEU PHE ARG ILE PHE ARG SEQRES 18 C 302 THR LEU GLY THR PRO ASP GLU VAL VAL TRP PRO GLY VAL SEQRES 19 C 302 THR SER MET PRO ASP TYR LYS PRO SER PHE PRO LYS TRP SEQRES 20 C 302 ALA ARG GLN ASP PHE SER LYS VAL VAL PRO PRO LEU ASP SEQRES 21 C 302 GLU ASP GLY ARG SER LEU LEU SER GLN MET LEU HIS TYR SEQRES 22 C 302 ASP PRO ASN LYS ARG ILE SER ALA LYS ALA ALA LEU ALA SEQRES 23 C 302 HIS PRO PHE PHE GLN ASP VAL THR LYS PRO VAL PRO HIS SEQRES 24 C 302 LEU ARG LEU SEQRES 1 D 260 MET GLU VAL PRO ASP TYR HIS GLU ASP ILE HIS THR TYR SEQRES 2 D 260 LEU ARG GLU MET GLU VAL LYS CYS LYS PRO LYS VAL GLY SEQRES 3 D 260 TYR MET LYS LYS GLN PRO ASP ILE THR ASN SER MET ARG SEQRES 4 D 260 ALA ILE LEU VAL ASP TRP LEU VAL GLU VAL GLY GLU GLU SEQRES 5 D 260 TYR LYS LEU GLN ASN GLU THR LEU HIS LEU ALA VAL ASN SEQRES 6 D 260 TYR ILE ASP ARG PHE LEU SER SER MET SER VAL LEU ARG SEQRES 7 D 260 GLY LYS LEU GLN LEU VAL GLY THR ALA ALA MET LEU LEU SEQRES 8 D 260 ALA SER LYS PHE GLU GLU ILE TYR PRO PRO GLU VAL ALA SEQRES 9 D 260 GLU PHE VAL TYR ILE THR ASP ASP THR TYR THR LYS LYS SEQRES 10 D 260 GLN VAL LEU ARG MET GLU HIS LEU VAL LEU LYS VAL LEU SEQRES 11 D 260 THR PHE ASP LEU ALA ALA PRO THR VAL ASN GLN PHE LEU SEQRES 12 D 260 THR GLN TYR PHE LEU HIS GLN GLN PRO ALA ASN CYS LYS SEQRES 13 D 260 VAL GLU SER LEU ALA MET PHE LEU GLY GLU LEU SER LEU SEQRES 14 D 260 ILE ASP ALA ASP PRO TYR LEU LYS TYR LEU PRO SER VAL SEQRES 15 D 260 ILE ALA GLY ALA ALA PHE HIS LEU ALA LEU TYR THR VAL SEQRES 16 D 260 THR GLY GLN SER TRP PRO GLU SER LEU ILE ARG LYS THR SEQRES 17 D 260 GLY TYR THR LEU GLU SER LEU LYS PRO CYS LEU MET ASP SEQRES 18 D 260 LEU HIS GLN THR TYR LEU LYS ALA PRO GLN HIS ALA GLN SEQRES 19 D 260 GLN SER ILE ARG GLU LYS TYR LYS ASN SER LYS TYR HIS SEQRES 20 D 260 GLY VAL SER LEU LEU ASN PRO PRO GLU THR LEU ASN LEU MODRES 1OIU TPO A 160 THR PHOSPHOTHREONINE MODRES 1OIU TPO C 160 THR PHOSPHOTHREONINE HET TPO A 160 11 HET TPO C 160 11 HET N76 A1298 28 HET SGM B1193 6 HET MG B1433 1 HET N76 C1298 28 HET SGM D1193 6 HETNAM TPO PHOSPHOTHREONINE HETNAM N76 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)- HETNAM 2 N76 BENZENESULFONAMIDE HETNAM SGM MONOTHIOGLYCEROL HETNAM MG MAGNESIUM ION HETSYN TPO PHOSPHONOTHREONINE FORMUL 1 TPO 2(C4 H10 N O6 P) FORMUL 5 N76 2(C18 H22 N6 O3 S) FORMUL 6 SGM 2(C3 H8 O2 S) FORMUL 7 MG MG 2+ FORMUL 10 HOH *646(H2 O) HELIX 1 1 SER A 0 GLU A 2 5 3 HELIX 2 2 PRO A 45 LEU A 58 1 14 HELIX 3 3 LEU A 87 SER A 94 1 8 HELIX 4 4 PRO A 100 HIS A 121 1 22 HELIX 5 5 LYS A 129 GLN A 131 5 3 HELIX 6 6 ASP A 145 ALA A 149 5 5 HELIX 7 7 THR A 165 ARG A 169 5 5 HELIX 8 8 ALA A 170 LEU A 175 1 6 HELIX 9 9 THR A 182 ARG A 199 1 18 HELIX 10 10 SER A 207 GLY A 220 1 14 HELIX 11 11 GLY A 229 MET A 233 5 5 HELIX 12 12 ASP A 247 VAL A 252 1 6 HELIX 13 13 ASP A 256 LEU A 267 1 12 HELIX 14 14 SER A 276 LEU A 281 1 6 HELIX 15 15 ALA A 282 GLN A 287 5 6 HELIX 16 16 TYR B 178 CYS B 193 1 16 HELIX 17 17 GLY B 198 GLN B 203 5 6 HELIX 18 18 THR B 207 TYR B 225 1 19 HELIX 19 19 GLN B 228 SER B 244 1 17 HELIX 20 20 LEU B 249 GLY B 251 5 3 HELIX 21 21 LYS B 252 GLU B 269 1 18 HELIX 22 22 GLU B 274 THR B 282 1 9 HELIX 23 23 THR B 287 LEU B 302 1 16 HELIX 24 24 THR B 310 PHE B 319 1 10 HELIX 25 25 LEU B 320 GLN B 322 5 3 HELIX 26 26 ASN B 326 ASP B 343 1 18 HELIX 27 27 ASP B 343 LEU B 348 1 6 HELIX 28 28 LEU B 351 GLY B 369 1 19 HELIX 29 29 PRO B 373 GLY B 381 1 9 HELIX 30 30 THR B 383 ALA B 401 1 19 HELIX 31 31 PRO B 402 HIS B 404 5 3 HELIX 32 32 GLN B 407 TYR B 413 1 7 HELIX 33 33 LYS B 414 HIS B 419 5 6 HELIX 34 34 GLY B 420 LEU B 424 5 5 HELIX 35 35 PRO C 45 LEU C 58 1 14 HELIX 36 36 LEU C 87 SER C 94 1 8 HELIX 37 37 PRO C 100 HIS C 121 1 22 HELIX 38 38 LYS C 129 GLN C 131 5 3 HELIX 39 39 ASP C 145 ALA C 149 5 5 HELIX 40 40 THR C 165 ARG C 169 5 5 HELIX 41 41 ALA C 170 LEU C 175 1 6 HELIX 42 42 THR C 182 ARG C 199 1 18 HELIX 43 43 SER C 207 GLY C 220 1 14 HELIX 44 44 ASP C 256 LEU C 267 1 12 HELIX 45 45 SER C 276 LEU C 281 1 6 HELIX 46 46 ALA C 282 GLN C 287 5 6 HELIX 47 47 TYR D 178 CYS D 193 1 16 HELIX 48 48 GLY D 198 GLN D 203 5 6 HELIX 49 49 THR D 207 TYR D 225 1 19 HELIX 50 50 GLN D 228 MET D 246 1 19 HELIX 51 51 LEU D 249 GLY D 251 5 3 HELIX 52 52 LYS D 252 GLU D 269 1 18 HELIX 53 53 GLU D 274 THR D 282 1 9 HELIX 54 54 THR D 287 LEU D 302 1 16 HELIX 55 55 THR D 310 LEU D 320 1 11 HELIX 56 56 ASN D 326 ASP D 343 1 18 HELIX 57 57 ASP D 343 LEU D 348 1 6 HELIX 58 58 LEU D 351 GLY D 369 1 19 HELIX 59 59 PRO D 373 GLY D 381 1 9 HELIX 60 60 LEU D 387 ALA D 401 1 15 HELIX 61 61 PRO D 402 HIS D 404 5 3 HELIX 62 62 GLN D 407 TYR D 413 1 7 HELIX 63 63 LYS D 414 HIS D 419 5 6 HELIX 64 64 GLY D 420 LEU D 424 5 5 SHEET 1 AA 5 PHE A 4 GLY A 11 0 SHEET 2 AA 5 VAL A 17 ASN A 23 -1 O VAL A 18 N ILE A 10 SHEET 3 AA 5 VAL A 29 ARG A 36 -1 O VAL A 30 N ALA A 21 SHEET 4 AA 5 LYS A 75 GLU A 81 -1 O LEU A 76 N ILE A 35 SHEET 5 AA 5 LEU A 66 HIS A 71 -1 N LEU A 67 O VAL A 79 SHEET 1 AB 3 GLN A 85 ASP A 86 0 SHEET 2 AB 3 LEU A 133 ILE A 135 -1 O ILE A 135 N GLN A 85 SHEET 3 AB 3 ILE A 141 LEU A 143 -1 O LYS A 142 N LEU A 134 SHEET 1 AC 2 VAL A 123 LEU A 124 0 SHEET 2 AC 2 ARG A 150 ALA A 151 -1 O ARG A 150 N LEU A 124 SHEET 1 CA 5 PHE C 4 GLY C 11 0 SHEET 2 CA 5 VAL C 17 ASN C 23 -1 O VAL C 18 N ILE C 10 SHEET 3 CA 5 VAL C 29 ARG C 36 -1 O VAL C 30 N ALA C 21 SHEET 4 CA 5 LYS C 75 GLU C 81 -1 O LEU C 76 N ILE C 35 SHEET 5 CA 5 LEU C 66 HIS C 71 -1 N LEU C 67 O VAL C 79 SHEET 1 CB 3 GLN C 85 ASP C 86 0 SHEET 2 CB 3 LEU C 133 ILE C 135 -1 O ILE C 135 N GLN C 85 SHEET 3 CB 3 ILE C 141 LEU C 143 -1 O LYS C 142 N LEU C 134 SHEET 1 CC 2 VAL C 123 LEU C 124 0 SHEET 2 CC 2 ARG C 150 ALA C 151 -1 O ARG C 150 N LEU C 124 LINK C TYR A 159 N TPO A 160 1555 1555 1.34 LINK C TPO A 160 N HIS A 161 1555 1555 1.33 LINK C TYR C 159 N TPO C 160 1555 1555 1.33 LINK C TPO C 160 N HIS C 161 1555 1555 1.33 LINK O MET B 200 MG MG B1433 1555 1555 2.85 LINK O GLN B 203 MG MG B1433 1555 1555 2.29 LINK O ILE B 206 MG MG B1433 1555 1555 2.46 LINK MG MG B1433 O HOH B2050 1555 1555 2.60 LINK MG MG B1433 O HOH B2051 1555 1555 2.55 LINK MG MG B1433 O HOH B2052 1555 1555 2.74 CISPEP 1 VAL A 154 PRO A 155 0 -4.95 CISPEP 2 GLN B 323 PRO B 324 0 -3.39 CISPEP 3 ASP B 345 PRO B 346 0 10.60 CISPEP 4 VAL C 154 PRO C 155 0 -5.67 CISPEP 5 GLN D 323 PRO D 324 0 0.53 CISPEP 6 ASP D 345 PRO D 346 0 8.63 SITE 1 AC1 6 MET B 200 GLN B 203 ILE B 206 HOH B2050 SITE 2 AC1 6 HOH B2051 HOH B2052 SITE 1 AC2 14 ILE A 10 GLU A 12 GLY A 13 ALA A 31 SITE 2 AC2 14 VAL A 64 PHE A 80 GLU A 81 PHE A 82 SITE 3 AC2 14 LEU A 83 HIS A 84 ASN A 132 LEU A 134 SITE 4 AC2 14 HOH A2014 HOH A2090 SITE 1 AC3 16 ILE C 10 GLU C 12 GLY C 13 ALA C 31 SITE 2 AC3 16 VAL C 64 PHE C 80 GLU C 81 PHE C 82 SITE 3 AC3 16 LEU C 83 HIS C 84 ASP C 86 ASN C 132 SITE 4 AC3 16 LEU C 134 HOH C2061 HOH C2127 HOH C2128 SITE 1 AC4 8 HOH A2044 MET B 189 LYS B 192 CYS B 193 SITE 2 AC4 8 ARG B 241 ASP B 305 HOH B2186 HOH B2187 SITE 1 AC5 4 LYS D 192 CYS D 193 ARG D 241 HOH D2112 CRYST1 73.648 133.778 148.228 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.013578 0.000000 0.000000 0.00000 SCALE2 0.000000 0.007475 0.000000 0.00000 SCALE3 0.000000 0.000000 0.006746 0.00000 MTRIX1 1 0.031570 -0.514050 0.857180 11.53561 1 MTRIX2 1 -0.508190 -0.746740 -0.429100 143.03769 1 MTRIX3 1 0.860670 -0.422060 -0.284810 70.33099 1 MTRIX1 2 0.042670 -0.494360 0.868210 9.42328 1 MTRIX2 2 -0.525790 -0.750040 -0.401240 142.78091 1 MTRIX3 2 0.849550 -0.439370 -0.291930 71.95583 1